Minimum clinically important differences identified for commonly used depression rating scales.

[1]  R. DeRubeis,et al.  Antidepressant drug effects and depression severity: a patient-level meta-analysis. , 2010, JAMA.

[2]  B. Fantino,et al.  The clinical relevance of changes in the Montgomery–Asberg Depression Rating Scale using the minimum clinically important difference approach , 2008 .

[3]  David Cella,et al.  Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. , 2008, The journal of pain : official journal of the American Pain Society.

[4]  Blair T. Johnson,et al.  Initial Severity and Antidepressant Benefits: A Meta-Analysis of Data Submitted to the Food and Drug Administration , 2008, PLoS medicine.

[5]  D. Stein,et al.  What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder? , 2006, The Journal of clinical psychiatry.

[6]  T. Furukawa,et al.  Gradations of clinical severity and sensitivity to change assessed with the Beck Depression Inventory-II in Japanese patients with depression , 2005, Psychiatry Research.

[7]  J. Markowitz,et al.  The 16-Item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression , 2003, Biological Psychiatry.

[8]  T. Gale,et al.  Defining remission by cut off score on the MADRS: selecting the optimal value. , 2002, Journal of affective disorders.

[9]  H. Wilson.  MINIMUM CLINICAL IMPORTANT DIFFERENCES OF HEALTH OUTCOMES IN A CHRONIC PAIN POPULATION: ARE THEY PREDICTIVE OF POOR OUTCOMES? , 2007 .